Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 2/20 | 0.54 |
| ▸ | MC5R | P33032 | 2/20 | 0.54 |
| ▸ | MC3R | P41968 | 2/20 | 0.54 |
| ▸ | MC1R | Q01726 | 2/20 | 0.54 |
| ▸ | TFPI | P10646 | 6/20 | 0.53 |
| ▸ | RAMP3 | O60896 | 10/20 | 0.53 |
| ▸ | CALCR | P30988 | 10/20 | 0.53 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | CTSH | P09668 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13028816 | 0.87 | TFPI (0.62) | MC4RMC5RMC3RMC1RTFPI | |
| SCHEMBL13028249 | 0.78 | REN (0.54) | TFPIRAMP3CALCR | |
| SCHEMBL12985531 | 0.78 | REN (0.54) | TFPIRAMP3CALCR | |
| SCHEMBL10066223 | 0.78 | REN (0.56) | MC4RMC5RMC3RMC1R | |
| SCHEMBL10066220 | 0.77 | REN (0.54) | MC4RMC5RMC3RMC1R | |
| SCHEMBL10066203 | 0.76 | RAMP3 (0.60) | TFPIRAMP3CALCR | |
| SCHEMBL13028975 | 0.76 | RAMP3 (0.65) | MC4RMC5RMC3RMC1RTFPI | |
| SCHEMBL14096140 | 0.76 | RAMP3 (0.60) | MC4RMC5RMC3RMC1RTFPI | |
| SCHEMBL12984646 | 0.74 | RAMP3 (0.63) | TFPIRAMP3CALCR | |
| SCHEMBL31437180 | 0.73 | CTSL (0.66) | MC4RMC5RMC3RMC1RCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100316563-A1 | Method For The Preparation Of New Oligoclonal Antibodies | BRACCO IMAGING S.P.A. (IT) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316563-A1 | Method For The Preparation Of New Oligoclonal Antibodies | APOB, APOL1, FCGR3B | MC4R 4810/4885MC5R 4570/4885MC3R 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.